Zoom Logo

Webinar: Improving Access to MNCH Products through Strengthening Registration - Shared screen with speaker view
Rajita Majumdar
21:50
Hello everyone! I am Rajita Majumdar with USAID MTaPS program: www.mtapsprogram.org
Zubayer HUssain
22:49
Hello, This is Zubayer Hussain from USAID MTaPS.
Michel Pacqué
23:21
Michel Pacqué, JSI RESEARCH & TRAINING INSTITUTE, INC. --   Child Health Lead MOMENTUM Integrated Health Resilience
Bistra Zheleva
24:00
Hello, Bistra Zheleva, Children's HeartLink
Kate Kikule
24:22
Hello Kate Kikule, Principal Technical Advisor - Pharmaceutical Regulatory Systems MTaPS
Maimunat Alex-Adeomi
24:46
Hello everyone. Maimunat Alex-Adeomi. American Academy of Pediatrics
Manjari Quintanar
25:39
Good day! Manjari Quintanar, Medical Devices and Health Technologies at PATH
Patrick Gaparayi
26:44
Hello colleagues. I am Patrick Gaparayi, UNICEF Supply Division, Copenhagen
Sita Strother
33:27
Thank you all for coming! Feel free to add your questions in the chat.
Fatima Gohar
36:48
I was surprised not to see Malawi in having a registration mechanism for medical devices - I hope I have not missed it
Jane Briggs
47:14
Sorry - Malawi was not studied in this exercise- there were only 9 countries
Fatima Gohar
49:28
Thanks @Jane and @Kate...
Smita Kumar
51:09
@Fatima - The 9 countries studied were: Nepal, Bangladesh, Mali, Senegal, Rwanda, Tanzania, Uganda and the DRC
Fatima Gohar
51:40
Thank you @Smita,
Jane Briggs
51:41
and Mozambique
Patrick Gaparayi
51:56
Questions to Jane: (1) During your survey, is there any possible correlation between the number of registered products and the number of importers/manufacturers/market authorization holders? (2) Is there any evidence that adequate product registration in a given country would impact positively on its availability at the service delivery points? (3) What could be your interpretation on a product like Ceftriaxone that has more than 200 market authorization holders in Bangladesh (maybe it is a red flag)?
MADU EZIOMA
52:33
honestly am so surprise to see that NEPAL is not having 4% chlorhexidine gel in their list of medical registration. In 2012 a team of health professionals visited Nepal for experience sharing on the use of 4% chlorhexidine gel application in their country. A success story. What happened planned now?
MADU EZIOMA
53:13
What happened now?
Jane Briggs
56:49
CHX is registered in Nepal- it is one of the few registered products - it was shown in blue on the table as having 1-2 products registered
Jane Briggs
57:42
Here is the link to the technical document of this mapping
Jane Briggs
57:46
https://www.mtapsprogram.org/our-resources/improving-access-to-maternal-newborn-and-child-health-medical-products-in-low-and-middle-income-countries-considerations-for-effective-registration-systems/
Siobhan Vega
01:06:51
The information on registration fees is interesting but only one cost to the supplier to register products. Do you have any information on the LOE and costs to prepare, submit etc dossiers per county? Thank you
Jane Briggs
01:13:01
thanks for your interest in this webinar - we will share the recording and the presentations and you already have the link to the report
Jane Briggs
01:13:21
Feel free to reach out to us with any specific questions you may have
Bistra Zheleva
01:13:47
very interesting results and unfortunately lots of work to be done. Question: in a recent assessment of cardiovascular services in Africa, this problem for lack of specialized supplies and medicines emerged for many countries. Those tend to be the opposite - high cost and low volume but companies also were not interested in even entering the markets because of perceived lack of market opportunities. Any suggestions on how to approach that challenge?
Montse Renom-Llonch
01:14:22
Did you find differences in imported versus locally produced commodities in the registration process? Do you know of countries which government promotes/incentives local production?
Elizabeth Abu-Haydar
01:15:07
thank you for this great webinar